Record-Breaking Revenue and Growth
Q3 2025 revenue was a record $32 million, increasing 45% versus Q3 2024. Gross profit reached a record $16.2 million with gross margins of 50.6%. Adjusted EBITDA was $1.6 million, marking the sixth consecutive quarter of profitability.
Significant Market Advantage
Owlet, Inc.'s DreamSock is the first FDA-cleared over-the-counter infant monitoring device. This FDA clearance provides a significant competitive advantage in the market.
Global Expansion Success
International revenue growth surged 171% year over year. The company received regulatory clearance to distribute DreamSock in India, expanding its global reach.
Strong Owlet 360 Subscription Growth
Total paying subscribers surpassed 85,000, with the subscription attach rate for DreamSock passing 25% by the end of Q3 2025.
Strategic Rhapsody Partnership
The Rhapsody partnership enhances the value proposition of BabySat, allowing real-time data access for neonatologists and hospitals, facilitating rapid integration with hospital systems.
Successful Capital Market Activities
Completed a warrant exchange and equity offering, raising net proceeds of approximately $32 million to strengthen the balance sheet and support long-term growth.